<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24098692</article-id><article-id pub-id-type="pmc">3787093</article-id><article-id pub-id-type="publisher-id">PONE-D-13-21733</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0075353</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Unintended Pregnancy among HIV Positive Couples Receiving Integrated HIV Counseling, Testing, and Family Planning Services in Zambia</article-title><alt-title alt-title-type="running-head">Unintended Pregnancy in HIV Positive Couples</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wall</surname><given-names>Kristin M.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Haddad</surname><given-names>Lisa</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vwalika</surname><given-names>Bellington</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Htee Khu</surname><given-names>Naw</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Brill</surname><given-names>Ilene</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kilembe</surname><given-names>William</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Stephenson</surname><given-names>Rob</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chomba</surname><given-names>Elwyn</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vwalika</surname><given-names>Cheswa</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tichacek</surname><given-names>Amanda</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Allen</surname><given-names>Susan</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Rwanda Zambia HIV Research Group, Department of Pathology &#x00026; Laboratory Medicine, School of Medicine, Emory University, Atlanta, Georgia, United States of America</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Department of Gynecology and Obstetrics, Emory University, School of Medicine, Atlanta, Georgia, United States of America</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Department of Gynecology and Obstetrics, School of Medicine, University of Zambia, Lusaka, Zambia</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Department of Epidemiology, Ryals School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, United States of America</addr-line>
</aff><aff id="aff6">
<label>6</label>
<addr-line>Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America</addr-line>
</aff><aff id="aff7">
<label>7</label>
<addr-line>Ministry of Community Development, Mother and Child Health, Lusaka, Zambia</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Venter</surname><given-names>Willem Daniel Francois</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Wits Reproductive Health and HIV Institute, South Africa</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>kmwall@emory.edu</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: BV WK EC CV AT SA. Performed the experiments: BV WK EC CV AT SA. Analyzed the data: KW LH NHK IB RS SA. Wrote the paper: KW LH BV NHK IB WK RS EC CV AT SA. Contributed to the conception and design of the study: BV WK EC CV AT SA. Contributed to the analysis and interpretation of data: KW LH NHK IB RS. Drafted the article: KW LH NHK IB RS. Revised article critically for important intellectual content and gave final approval of the version to be published: KW LH NHK IB RS BV WK EC CV AT SA.</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>30</day><month>9</month><year>2013</year></pub-date><volume>8</volume><issue>9</issue><elocation-id>e75353</elocation-id><history><date date-type="received"><day>27</day><month>5</month><year>2013</year></date><date date-type="accepted"><day>12</day><month>8</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2013 Wall et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Wall et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>We describe rates of unintended pregnancy among HIV positive couples in Lusaka, Zambia. We also identify factors associated with unintended pregnancy among oral contraceptive pill (OCP) using couples in this cohort.</p></sec><sec><title>Design</title><p>Data were analyzed from couples randomized in a factorial design to two family planning intervention videos.</p></sec><sec><title>Methods</title><p>Rates of unintended pregnancy were stratified by contraceptive method used at time of pregnancy. Predictors of time to unintended pregnancy among OCP users were determined via multivariate Cox modeling.</p></sec><sec><title>Results</title><p>The highest rates of unintended pregnancy were observed among couples requesting condoms only (26.4/100CY) or OCPs (20.7/100CY); these rates were not significantly different. OCP users accounted for 37% of the couple-years (CY) observed and 87% of unintended pregnancies. Rates of unintended pregnancy for injectable (0.7/100CY) and intrauterine device (1.6/100CY) users were significantly lower relative to condom only users. No pregnancies occurred among contraceptive implant users or after tubal ligation. Factors associated (p&#x0003c;0.05) with time to unintended pregnancy among OCP users in multivariate analysis included the man wanting more children, the woman being HIV negative versus having stage IV HIV disease, and the woman reporting: younger age, no previous OCP use, missed OCPs, or sex without a condom.</p></sec><sec><title>Conclusions</title><p>Long-acting reversible contraceptive methods were effective in the context of integrated couples HIV prevention and contraceptive services. Injectable methods were also effective in this context. Given the high user failure rate of OCPs, family planning efforts should promote longer-acting methods among OCP users wishing to avoid pregnancy. Where other methods are not available or acceptable, OCP adherence counseling is needed, especially among younger and new OCP users.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00067522?term=NCT00067522&#x00026;rank=1">NCT00067522</ext-link>
</p></sec></abstract><funding-group><funding-statement>This work was supported by funding from the National Institutes of Child Health and Development (NICHD RO1 HD40125); National Institute of Mental Health (NIMH R01 66767); the AIDS International Training and Research Program Fogarty International Center (D43 TW001042); the Emory Center for AIDS Research (P30 AI050409); National Institute of Allergy and Infectious Diseases (NIAID R01 AI51231); and the International AIDS Vaccine Initiative. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="10"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Though the Total Fertility Rate (TFR), or average number of births a woman has in her lifetime, has declined in sub-Saharan Africa from 6.5 in 1950 to 5.1 in 2010, this trend has not been sufficient to address the region&#x02019;s rapid population growth of 2.5% per year <xref rid="pone.0075353-Bongaarts1" ref-type="bibr">[1]</xref>. As fertility preferences are changing, family planning programs are falling short in meeting couples&#x02019; fertility needs. The Demographic and Health Surveys estimate that 10&#x02013;65% of all pregnancies in the region are unintended, varying by country and age group <xref rid="pone.0075353-Demographic1" ref-type="bibr">[2]</xref>. Preventing unintended pregnancy via contraception, a key public health challenge, reduces maternal and child mortality, rates of abortion, and poverty while improving socioeconomic status, access to education, and gender equity <xref rid="pone.0075353-Tsui1" ref-type="bibr">[3]</xref>&#x02013;<xref rid="pone.0075353-Adinma1" ref-type="bibr">[7]</xref>. Up to an estimated 40% reduction in maternal deaths related to unintended pregnancy could be achieved with contraceptive use <xref rid="pone.0075353-Campbell1" ref-type="bibr">[6]</xref>. Additionally, in countries with generalized HIV epidemics and low contraceptive use, improving family planning services among HIV positive and high-risk women is critically important to reduce unintended pregnancy and the burden of mother-to-child transmission of HIV.</p><p>Unintended pregnancies occur primarily due to unmet need for contraception as well as reliance on less effective, user-dependent, short-acting methods. Unmet contraceptive need in sub-Saharan Africa is high, surpassing 30% in some countries <xref rid="pone.0075353-Cleland1" ref-type="bibr">[8]</xref>. About one-third of unintended pregnancies occur among women accessing contraception, many of whom are using short-term methods that require user adherence on a daily or quarterly basis such as condoms, oral contraceptive pills (OCPs), and depo-medroxyprogesterone acetate (DMPA) injectables <xref rid="pone.0075353-Zuehlke1" ref-type="bibr">[9]</xref>, <xref rid="pone.0075353-Hubacher1" ref-type="bibr">[10]</xref>. Differential obstacles in adherence to short-term versus long-term reversible contraceptive methods, such as the intrauterine device (IUD) and implant, translate into differences in typical-use method failure rates. Estimated 1-year failure rates among women with typical-use are 15% for condoms, 8% for OCPs, 3% for DMPA, and &#x0003c;1% for the IUD and implant <xref rid="pone.0075353-Trussell1" ref-type="bibr">[11]</xref>, <xref rid="pone.0075353-Trussell2" ref-type="bibr">[12]</xref>.</p><p>Difficulties with contraception adherence are compounded in limited resource countries where economic and infrastructure barriers, such as transportation costs/reliability or clinic supply chain interruptions, are obstacles to the repeat clinic visits required for adherence to shorter-acting methods <xref rid="pone.0075353-Gribble1" ref-type="bibr">[13]</xref>&#x02013;<xref rid="pone.0075353-Nalwadda2" ref-type="bibr">[16]</xref>. Published data from several studies in sub-Saharan Africa suggest much higher typical-use failure rates. Some HIV prevention studies, including phase 2 and 3 microbicide trials, have observed annual pregnancy rates of up to 64/100 PY despite monthly contraceptive counseling <xref rid="pone.0075353-Ramjee1" ref-type="bibr">[17]</xref>&#x02013;<xref rid="pone.0075353-Peterson2" ref-type="bibr">[19]</xref>.</p><p>Without the need for repeat clinic visits or daily adherence, long-acting reversible contraceptive (LARC) methods provide 3&#x02013;5 years of protection from pregnancy with contraceptive implants (Jadelle, Sino-Implant, Implanon) and up to 12 years with the copper IUD <xref rid="pone.0075353-Population1" ref-type="bibr">[20]</xref>&#x02013;<xref rid="pone.0075353-Hatcher1" ref-type="bibr">[22]</xref>. Additionally, these methods are more cost-effective over time. Median direct cost per couple-year of protection against unintended pregnancy is lowest for the IUD ($1.64) and Sino-implant ($4.02) and is similar for Jadelle, DMPA, and OCPs ($7.90 to $8.70) <xref rid="pone.0075353-Janowitz1" ref-type="bibr">[23]</xref>. However, use of these highly effective and cost-effective LARC methods remains extremely low; use of modern methods among married Zambian women is 11% OCP, 8.5% injectable, 0.4% implant, and 0.1% IUD <xref rid="pone.0075353-Central1" ref-type="bibr">[24]</xref>.</p><p>In Zambia, where HIV prevalence among reproductive age individuals is high (23.1% in urban areas and 10.8% in rural areas) <xref rid="pone.0075353-UNAIDSWHO1" ref-type="bibr">[25]</xref>, prevention of maternal-to-child HIV transmission and unintended pregnancy are dual priorities that could be addressed through integrating HIV prevention and family planning services <xref rid="pone.0075353-Wilcher1" ref-type="bibr">[26]</xref>&#x02013;<xref rid="pone.0075353-Delvaux1" ref-type="bibr">[29]</xref>. Unfortunately these programs are typically organized vertically, and integration can be difficult. Women often cite the importance of male partners in contraceptive method choice, continuation, and consistent condom use <xref rid="pone.0075353-Imbuki1" ref-type="bibr">[30]</xref>&#x02013;<xref rid="pone.0075353-Utoo1" ref-type="bibr">[32]</xref>, and HIV services that involve partners (such as couples&#x02019; voluntary HIV counseling and testing, CVCT), may observe higher typical-use contraception efficacy rates, particularly for the user-dependent methods <xref rid="pone.0075353-Shattuck1" ref-type="bibr">[33]</xref>.</p><p>We previously reported that a video-based intervention increased LARC method uptake among couples seeking CVCT in Lusaka, Zambia <xref rid="pone.0075353-Stephenson1" ref-type="bibr">[34]</xref>; however, that intervention increased time to pregnancy only among HIV positive women who were already contracepting prior to the study <xref rid="pone.0075353-Wall1" ref-type="bibr">[35]</xref>. The impact of contraceptive method choice on unintended pregnancy, among both HIV positive and high-risk HIV negative women in regions with high fertility and HIV incidence, remains largely unknown. The present analysis examines rates of unintended pregnancy among couples choosing different contraceptive options after the intervention, as well as predictors of unintended pregnancy among couples using OCPs, in order to improve program planning and patient counseling.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Ethics Statement</title><p>The study was approved by the Institutional Review Boards at Emory University and the University of Zambia. Written informed consent was obtained from all study participants.</p></sec><sec id="s2b"><title>Study Design</title><p>The demographics of the cohort <xref rid="pone.0075353-Stephenson2" ref-type="bibr">[36]</xref>; knowledge of, prior experience with, and concerns about modern contraceptive methods <xref rid="pone.0075353-Grabbe1" ref-type="bibr">[37]</xref>; impact of informed consent on contraceptive knowledge <xref rid="pone.0075353-Stephenson3" ref-type="bibr">[38]</xref> and planning behaviors <xref rid="pone.0075353-Stephenson4" ref-type="bibr">[39]</xref>; study and intervention design and uptake of contraception immediately after the intervention <xref rid="pone.0075353-Stephenson1" ref-type="bibr">[34]</xref>; and impact of the video-based interventions on incident pregnancy <xref rid="pone.0075353-Wall1" ref-type="bibr">[35]</xref> have been previously reported.</p><p>Briefly, we analyzed data from 1060 couples recruited from CVCT services in Lusaka, Zambia. Eligible couples had no contraception contraindications and were cohabiting at least 12 months, fecund, not currently pregnant, and concordant HIV positive (man and woman both positive) or HIV discordant (man and woman have different results). Eligible men and women were ages 18&#x02013;65 and 18&#x02013;45, respectively. Participants were randomized in a factorial design to view video-based interventions. A &#x0201c;Methods&#x0201d; video detailed family planning methods with a focus on LARC methods, a &#x0201c;Motivational&#x0201d; video modeled future planning behaviors, and a &#x0201c;Control&#x0201d; video contained information on topics such as hand washing, bed-nets, and nutrition. After the intervention, couples were offered the full range of contraceptive methods on-site and were followed at 3-month intervals, with the possibility for interim visits. Condoms were provided at each visit to all couples. Couples in which the man wanted children within the next year were not included in this analysis as they were not considered to be at risk of adopting a method.</p></sec><sec id="s2c"><title>Definitions</title><p>We defined a pregnancy as planned if it occurred after a woman discontinued her method because she reported a desire to become pregnant. All other pregnancies were considered unintended, specifically those occurring among women who reported using condoms and/or another contraceptive method and did not express a desire for pregnancy.</p></sec><sec id="s2d"><title>Analysis</title><p>Pregnancy incidence rates (number of pregnancies over the total couple-time) among women who did not desire pregnancy were calculated and stratified by the contraception method being used when the pregnancy occurred. Couple-time was attributed a method only when the woman was an active user. Thus, couples could contribute follow-up time to multiple methods. Significant differences between the rates of unintended pregnancy for each method relative to couples using only condoms were calculated using Mid-p exact tests.</p><p>OCP using couples were described (n/mean, %/SD) by fixed covariates of interest (including trial arm, sociodemographic characteristics, family planning and behavioral factors, and HIV-related health characteristics), and stratified by whether they experienced a pregnancy. Significant differences in the distribution of these covariates by pregnancy status were determined with Chi-square (or Fisher&#x02019;s Exact) tests.</p><p>Among OCP users only, we evaluated univariate associations between time to unintended pregnancy and fixed covariates as well as time-varying health and sexual-related covariates assessed at 3-monthly and interim visits via crude hazards ratios (cHRs). We then built a multivariate Cox model containing covariates significant (p&#x0003c;0.05) in the univariate. Multi-collinearity between model variables was assessed (taking condition indices &#x0003e;30 and variance decomposition proportions &#x0003e;0.5 as cutoffs). The proportional hazards assumption was confirmed for the time-independent covariates. Adjusted hazards ratios (aHRs) are presented for covariates in the final multivariate model. Data analysis was conducted with SAS v9.3 (Cary, NC).</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Unintended Pregnancy Rates</title><p>There were 137 pregnancies during 1428.7 couple-years (CY) of follow-up, 126 of which were unintended. The overall unintended pregnancy incidence rate was 8.8/100CY. Women who requested condoms only (26.4/100CY) and those using OCPs (20.7/100CY) experienced the highest rates of unintended pregnancy. These rates were not significantly different. The majority (87%) of all unintended pregnancies occurred among women using OCPs, who accounted for 37% of the CYs observed (<xref ref-type="table" rid="pone-0075353-t001">Table 1</xref>).</p><table-wrap id="pone-0075353-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0075353.t001</object-id><label>Table 1</label><caption><title>Unintended pregnancy incidence rates by method used at time of pregnancy.</title></caption><alternatives><graphic id="pone-0075353-t001-1" xlink:href="pone.0075353.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Number of unintended pregnancies</td><td align="left" rowspan="1" colspan="1">Follow-up time (CY)</td><td align="left" rowspan="1" colspan="1">Pregnancy incidence per (100 CY)</td><td align="left" rowspan="1" colspan="1">95%CI</td><td align="left" rowspan="1" colspan="1">p value<xref ref-type="table-fn" rid="nt101">*</xref>
</td></tr></thead><tbody><tr><td colspan="2" align="left" rowspan="1">
<bold>Pregnancies occurring on:</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Condom<xref ref-type="table-fn" rid="nt102">&#x000a7;</xref>
</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">45.42</td><td align="left" rowspan="1" colspan="1">26.42</td><td align="left" rowspan="1" colspan="1">14.31, 44.92</td><td align="left" rowspan="1" colspan="1">ref</td></tr><tr><td align="left" rowspan="1" colspan="1">Oral contraceptive pill</td><td align="left" rowspan="1" colspan="1">109</td><td align="left" rowspan="1" colspan="1">527.24</td><td align="left" rowspan="1" colspan="1">20.67</td><td align="left" rowspan="1" colspan="1">17.06, 24.84</td><td align="left" rowspan="1" colspan="1">0.415</td></tr><tr><td align="left" rowspan="1" colspan="1">Injectable#</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">541.07</td><td align="left" rowspan="1" colspan="1">0.74</td><td align="left" rowspan="1" colspan="1">0.23, 1.78</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Intrauterine device ?</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">64.71</td><td align="left" rowspan="1" colspan="1">1.55</td><td align="left" rowspan="1" colspan="1">0.08, 7.62</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Implant</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">221.15</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">0.00, 8.51</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Tubal ligation</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">29.09</td><td align="left" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">0.00, 6.37</td><td align="left" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>126</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1428.68</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>8.82</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>7.38, 10.46</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label>*</label><p>2-tail Mid-p exact test p value.</p></fn><fn id="nt102"><label>&#x000a7;</label><p>Chose to receive no method other than condoms, which were provided to all couples.</p></fn><fn id="nt103"><label/><p>
<bold>#4 pregnancies on Injectable: N&#x0200a;=&#x0200a;1 user failure</bold> (22 weeks between injection and pregnancy date); <bold>N&#x0200a;=&#x0200a;2 user failures</bold> (24 weeks between injections); <bold>N&#x0200a;=&#x0200a;1 neither method nor user failure</bold> (Client likely in very early stages of pregnancy at enrollment, undetected by initial pregnancy test).</p></fn><fn id="nt104"><label>?</label><p>1 <bold>pregnancy on Intrauterine device: N&#x0200a;=&#x0200a;1 method failure</bold> (Intrauterine device was protruding at external os of cervix and easily removed at the time pregnancy detected).</p></fn></table-wrap-foot></table-wrap><p>The pregnancy incidence among women using injectables was 0.7/100CY and among women using IUDs was 1.6/100CY, with no pregnancies occurring on the contraceptive implant or after tubal ligation. Pregnancy rates were significantly lower (p&#x0003c;0.05) for injectable, IUD, contraceptive implant, and tubal ligation users relative to condom-only users.</p><p>Three of the four pregnancies occurring on injectables were classified as user failures (i.e., women were non-adherent with &#x0003e;15 weeks between the last injection and pregnancy date). The remaining pregnancy was likely in very early gestation at enrollment, with the pregnancy only becoming manifest after an initial negative pregnancy test and after the first injection was given. One IUD expulsion (a method failure) resulted in a pregnancy (<xref ref-type="table" rid="pone-0075353-t001">Table 1</xref> footnotes).</p></sec><sec id="s3b"><title>Descriptive Results: OCP Users</title><p>Five hundred and thirteen women used OCPs at some point during follow-up, of whom 109 (21.2%) experienced an unintended pregnancy. OCP users were on average 28.4 years of age for women and 34.4 years of age for men, and couples had an average of 2.1 living children at baseline. OCP users who did not become pregnant were older and had a higher monthly household income relative to those with a pregnancy (p&#x0003c;0.05).</p><p>Most women (63%) and men (52%) did not want more children. The man&#x02019;s desire for a child was associated with significantly unintended pregnancy (p&#x0200a;=&#x0200a;0.002); among couples experiencing an unintended pregnancy, 57% of men reported wanting a child, though not in the next year, at baseline versus 39% for non-pregnant couples.</p><p>Almost three-quarters (73%) of couples were using no modern method of contraception pre-randomization. About two-thirds of women (68%) reported ever having used OCPs previously. Significantly fewer women experiencing unintended pregnancy reported previous OCP use (57%) compared with those not experiencing an unintended pregnancy (71%) (p&#x0200a;=&#x0200a;0.009). At enrollment, 27% of women had ever used injectables, and only 2% reported ever using implant or IUD. Worries, concerns, or fears about contraception reported by women were highest for OCPs (88%) and lowest for the implant and IUD (37% and 39%, respectively). Most (89%) women reported engaging in sex without a condom with the study partner at some point during follow-up, and 95% women reported having missed taking at least one OCP at some point during follow-up.</p><p>Over two-thirds (68%) of couples were concordant HIV positive. OCP using women who became pregnant during follow-up were less likely to have advanced (stage IV) HIV disease relative to OCP using women who did not experience a pregnancy (2% versus 13%) (<xref ref-type="table" rid="pone-0075353-t002">Table 2</xref>).</p><table-wrap id="pone-0075353-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0075353.t002</object-id><label>Table 2</label><caption><title>Fixed sociodemographic, family planning and behavioral, and health characteristics among OCP users.</title></caption><alternatives><graphic id="pone-0075353-t002-2" xlink:href="pone.0075353.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Total OCP users (N&#x0200a;=&#x0200a;513)</td><td colspan="2" align="left" rowspan="1">Unintended pregnancy during follow-up (N&#x0200a;=&#x0200a;109)</td><td colspan="2" align="left" rowspan="1">No pregnancy during follow-up (N&#x0200a;=&#x0200a;404)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">n/mean</td><td align="left" rowspan="1" colspan="1">%/SD</td><td align="left" rowspan="1" colspan="1">n/mean</td><td align="left" rowspan="1" colspan="1">%/SD</td><td align="left" rowspan="1" colspan="1">n/mean</td><td align="left" rowspan="1" colspan="1">%/SD</td><td align="left" rowspan="1" colspan="1">p value<xref ref-type="table-fn" rid="nt105">*</xref>
</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Arm of trial</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Methods video</td><td align="left" rowspan="1" colspan="1">240</td><td align="left" rowspan="1" colspan="1">47%</td><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1">47%</td><td align="left" rowspan="1" colspan="1">189</td><td align="left" rowspan="1" colspan="1">47%</td><td align="left" rowspan="1" colspan="1">0.999</td></tr><tr><td align="left" rowspan="1" colspan="1">No Methods video</td><td align="left" rowspan="1" colspan="1">273</td><td align="left" rowspan="1" colspan="1">53%</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">53%</td><td align="left" rowspan="1" colspan="1">215</td><td align="left" rowspan="1" colspan="1">53%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Arm of trial</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Motivational video</td><td align="left" rowspan="1" colspan="1">259</td><td align="left" rowspan="1" colspan="1">50%</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">44%</td><td align="left" rowspan="1" colspan="1">211</td><td align="left" rowspan="1" colspan="1">52%</td><td align="left" rowspan="1" colspan="1">0.129</td></tr><tr><td align="left" rowspan="1" colspan="1">No Motivational video</td><td align="left" rowspan="1" colspan="1">254</td><td align="left" rowspan="1" colspan="1">50%</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">56%</td><td align="left" rowspan="1" colspan="1">193</td><td align="left" rowspan="1" colspan="1">48%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>Sociodemographics</italic></bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age of woman</bold>
</td><td align="left" rowspan="1" colspan="1">28.43</td><td align="left" rowspan="1" colspan="1">5.49</td><td align="left" rowspan="1" colspan="1">26.46</td><td align="left" rowspan="1" colspan="1">5.29</td><td align="left" rowspan="1" colspan="1">28.96</td><td align="left" rowspan="1" colspan="1">5.43</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age of man</bold>
</td><td align="left" rowspan="1" colspan="1">34.38</td><td align="left" rowspan="1" colspan="1">6.13</td><td align="left" rowspan="1" colspan="1">33.07</td><td align="left" rowspan="1" colspan="1">6.35</td><td align="left" rowspan="1" colspan="1">34.74</td><td align="left" rowspan="1" colspan="1">6.03</td><td align="left" rowspan="1" colspan="1">0.015</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>No. living children</bold>
</td><td align="left" rowspan="1" colspan="1">2.08</td><td align="left" rowspan="1" colspan="1">1.36</td><td align="left" rowspan="1" colspan="1">2.05</td><td align="left" rowspan="1" colspan="1">1.38</td><td align="left" rowspan="1" colspan="1">2.09</td><td align="left" rowspan="1" colspan="1">1.36</td><td align="left" rowspan="1" colspan="1">0.788</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Monthly household income (USD)</bold>
</td><td align="left" rowspan="1" colspan="1">67.12</td><td align="left" rowspan="1" colspan="1">112.58</td><td align="left" rowspan="1" colspan="1">49.02</td><td align="left" rowspan="1" colspan="1">48.28</td><td align="left" rowspan="1" colspan="1">71.96</td><td align="left" rowspan="1" colspan="1">123.86</td><td align="left" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>Family planning and behavioral</italic></bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Woman fertility intentions</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.146</td></tr><tr><td align="left" rowspan="1" colspan="1">Wants more children in the next year</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">6%</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">6%</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">6%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Wants more children, not in next year</td><td align="left" rowspan="1" colspan="1">148</td><td align="left" rowspan="1" colspan="1">29%</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">37%</td><td align="left" rowspan="1" colspan="1">108</td><td align="left" rowspan="1" colspan="1">27%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Does not know</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">2%</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3%</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">2%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Does not want more children</td><td align="left" rowspan="1" colspan="1">323</td><td align="left" rowspan="1" colspan="1">63%</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">54%</td><td align="left" rowspan="1" colspan="1">265</td><td align="left" rowspan="1" colspan="1">66%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Man fertility intentions</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Wants more children, not in next year</td><td align="left" rowspan="1" colspan="1">219</td><td align="left" rowspan="1" colspan="1">43%</td><td align="left" rowspan="1" colspan="1">62</td><td align="left" rowspan="1" colspan="1">57%</td><td align="left" rowspan="1" colspan="1">157</td><td align="left" rowspan="1" colspan="1">39%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Does not know</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">5%</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">6%</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">5%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Does not want more children</td><td align="left" rowspan="1" colspan="1">266</td><td align="left" rowspan="1" colspan="1">52%</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">37%</td><td align="left" rowspan="1" colspan="1">226</td><td align="left" rowspan="1" colspan="1">56%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Contraception methods ever used (past or at enrollment)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">OCPs</td><td align="left" rowspan="1" colspan="1">345</td><td align="left" rowspan="1" colspan="1">68%</td><td align="left" rowspan="1" colspan="1">62</td><td align="left" rowspan="1" colspan="1">57%</td><td align="left" rowspan="1" colspan="1">283</td><td align="left" rowspan="1" colspan="1">71%</td><td align="left" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1">INJ</td><td align="left" rowspan="1" colspan="1">135</td><td align="left" rowspan="1" colspan="1">27%</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">30%</td><td align="left" rowspan="1" colspan="1">103</td><td align="left" rowspan="1" colspan="1">26%</td><td align="left" rowspan="1" colspan="1">0.416</td></tr><tr><td align="left" rowspan="1" colspan="1">IMP or IUD</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">2%</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3%</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">2%</td><td align="left" rowspan="1" colspan="1">0.849</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Woman has worries, concerns, or fears about:</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">OCPs</td><td align="left" rowspan="1" colspan="1">449</td><td align="left" rowspan="1" colspan="1">88%</td><td align="left" rowspan="1" colspan="1">93</td><td align="left" rowspan="1" colspan="1">85%</td><td align="left" rowspan="1" colspan="1">356</td><td align="left" rowspan="1" colspan="1">89%</td><td align="left" rowspan="1" colspan="1">0.260</td></tr><tr><td align="left" rowspan="1" colspan="1">INJ</td><td align="left" rowspan="1" colspan="1">341</td><td align="left" rowspan="1" colspan="1">67%</td><td align="left" rowspan="1" colspan="1">73</td><td align="left" rowspan="1" colspan="1">68%</td><td align="left" rowspan="1" colspan="1">268</td><td align="left" rowspan="1" colspan="1">67%</td><td align="left" rowspan="1" colspan="1">0.856</td></tr><tr><td align="left" rowspan="1" colspan="1">IMP</td><td align="left" rowspan="1" colspan="1">167</td><td align="left" rowspan="1" colspan="1">37%</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">31%</td><td align="left" rowspan="1" colspan="1">139</td><td align="left" rowspan="1" colspan="1">39%</td><td align="left" rowspan="1" colspan="1">0.145</td></tr><tr><td align="left" rowspan="1" colspan="1">IUD</td><td align="left" rowspan="1" colspan="1">176</td><td align="left" rowspan="1" colspan="1">39%</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">37%</td><td align="left" rowspan="1" colspan="1">140</td><td align="left" rowspan="1" colspan="1">40%</td><td align="left" rowspan="1" colspan="1">0.613</td></tr><tr><td align="left" rowspan="1" colspan="1">BTL</td><td align="left" rowspan="1" colspan="1">171</td><td align="left" rowspan="1" colspan="1">43%</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">34%</td><td align="left" rowspan="1" colspan="1">144</td><td align="left" rowspan="1" colspan="1">45%</td><td align="left" rowspan="1" colspan="1">0.090</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Sex with partner in study without a condom reported by women (ever during follow-up)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.803</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">455</td><td align="left" rowspan="1" colspan="1">89%</td><td align="left" rowspan="1" colspan="1">96</td><td align="left" rowspan="1" colspan="1">88%</td><td align="left" rowspan="1" colspan="1">359</td><td align="left" rowspan="1" colspan="1">89%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">11%</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">12%</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">11%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Missed OCPs (ever during follow-up)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No missed OCPs reported</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">5%</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2%</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">6%</td><td align="left" rowspan="1" colspan="1">0.071</td></tr><tr><td align="left" rowspan="1" colspan="1">Any missed OCPs reported</td><td align="left" rowspan="1" colspan="1">486</td><td align="left" rowspan="1" colspan="1">95%</td><td align="left" rowspan="1" colspan="1">107</td><td align="left" rowspan="1" colspan="1">98%</td><td align="left" rowspan="1" colspan="1">379</td><td align="left" rowspan="1" colspan="1">94%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>Health: HIV</italic></bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>HIV serostatus at enrollment</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.241</td></tr><tr><td align="left" rowspan="1" colspan="1">Serodiscordant (woman is positive)</td><td align="left" rowspan="1" colspan="1">81</td><td align="left" rowspan="1" colspan="1">16%</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">20%</td><td align="left" rowspan="1" colspan="1">59</td><td align="left" rowspan="1" colspan="1">15%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Serodiscordant (man is positive)</td><td align="left" rowspan="1" colspan="1">84</td><td align="left" rowspan="1" colspan="1">16%</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">18%</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">16%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Concordant positive</td><td align="left" rowspan="1" colspan="1">348</td><td align="left" rowspan="1" colspan="1">68%</td><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1">61%</td><td align="left" rowspan="1" colspan="1">281</td><td align="left" rowspan="1" colspan="1">70%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Stage of HIV of woman</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">HIV negative</td><td align="left" rowspan="1" colspan="1">84</td><td align="left" rowspan="1" colspan="1">16%</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">18%</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">16%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage I&#x02013;II</td><td align="left" rowspan="1" colspan="1">216</td><td align="left" rowspan="1" colspan="1">42%</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">51%</td><td align="left" rowspan="1" colspan="1">160</td><td align="left" rowspan="1" colspan="1">40%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage III</td><td align="left" rowspan="1" colspan="1">159</td><td align="left" rowspan="1" colspan="1">31%</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">28%</td><td align="left" rowspan="1" colspan="1">128</td><td align="left" rowspan="1" colspan="1">32%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage IV</td><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1">11%</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2%</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">13%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Stage of HIV of man</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.440</td></tr><tr><td align="left" rowspan="1" colspan="1">HIV negative</td><td align="left" rowspan="1" colspan="1">81</td><td align="left" rowspan="1" colspan="1">16%</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">20%</td><td align="left" rowspan="1" colspan="1">59</td><td align="left" rowspan="1" colspan="1">15%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage I&#x02013;II</td><td align="left" rowspan="1" colspan="1">194</td><td align="left" rowspan="1" colspan="1">38%</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">39%</td><td align="left" rowspan="1" colspan="1">152</td><td align="left" rowspan="1" colspan="1">38%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage III</td><td align="left" rowspan="1" colspan="1">184</td><td align="left" rowspan="1" colspan="1">36%</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">33%</td><td align="left" rowspan="1" colspan="1">148</td><td align="left" rowspan="1" colspan="1">37%</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage IV</td><td align="left" rowspan="1" colspan="1">54</td><td align="left" rowspan="1" colspan="1">11%</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">8%</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">11%</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt105"><label>*</label><p>2-sided Chi-square (or Fisher&#x02019;s Exact) test p value.</p></fn><fn id="nt106"><label/><p>OCP: oral contraceptive pill; INJ: injectable contraception; IUD: intrauterine device; IMP: implant; BTL: bilateral tubal ligation; USD: United States Dollar.</p></fn><fn id="nt107"><label/><p>Numbers may not add to column totals due to missing values or if question inapplicable.</p></fn><fn id="nt108"><label/><p>Additional factors evaluated and not found to be significant included: Woman understands Nyanja, man understands Nyanja, who decides when/if you should have children (reported by woman), who decides when/if you should have children (reported by man), number of lifetime sexual partners reported by woman (per partner increase), age at first intercourse reported by woman (per year increase), and the following time varying health factors: heavy menstrual bleeding, irregular bleeding, dyspareunia, lower abdominal pain, bleeding between periods, cystitis/dysuria, vaginal discharge, acute genital ulcer.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><title>Modeling Results: OCP Users</title><p>Woman&#x02019;s and man&#x02019;s age were collinear and only woman&#x02019;s age was retained in the final model (<xref ref-type="table" rid="pone-0075353-t003">Table 3</xref>). In a multivariate Cox model containing time-varying covariates, factors associated (p&#x0003c;0.05) with unintended pregnancy among OCP users were the younger age of the woman partner (aHR&#x0200a;=&#x0200a;0.95 per year increase), the man wanting more children (though not in the next year) at baseline (aHR&#x0200a;=&#x0200a;1.58), the woman never having used OCPs previously (aHR&#x0200a;=&#x0200a;1.54), the woman reporting any sex without a condom (aHR&#x0200a;=&#x0200a;1.83), and the woman reporting any missed OCPs (aHR&#x0200a;=&#x0200a;1.86). Women with Stage IV HIV disease at baseline were less likely to become pregnant during follow-up (aHR&#x0200a;=&#x0200a;0.16). None of the time-varying health characteristics were significant (p&#x0003c;0.05) in the multivariate model. The &#x0201c;Methods&#x0201d; and &#x0201c;Motivational&#x0201d; intervention videos did not impact the time to unintended pregnancy among OCP users, nor did the interaction of both videos.</p><table-wrap id="pone-0075353-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0075353.t003</object-id><label>Table 3</label><caption><title>Extended Cox models of factors associated with time to unintended pregnancy among OCP users.</title></caption><alternatives><graphic id="pone-0075353-t003-3" xlink:href="pone.0075353.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="4" align="left" rowspan="1">UNIVARIATE</td><td colspan="4" align="left" rowspan="1">MULTIVARIATE</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">cHR</td><td colspan="2" align="left" rowspan="1">95%CI</td><td align="left" rowspan="1" colspan="1">p value</td><td align="left" rowspan="1" colspan="1">aHR</td><td colspan="2" align="left" rowspan="1">95%CI</td><td align="left" rowspan="1" colspan="1">p value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Arm of trial</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Methods video</td><td align="left" rowspan="1" colspan="1">ref</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No Methods video</td><td align="left" rowspan="1" colspan="1">1.03</td><td align="left" rowspan="1" colspan="1">0.71</td><td align="left" rowspan="1" colspan="1">1.50</td><td align="left" rowspan="1" colspan="1">0.884</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Arm of trial</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Motivational video</td><td align="left" rowspan="1" colspan="1">ref</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No Motivational video</td><td align="left" rowspan="1" colspan="1">1.13</td><td align="left" rowspan="1" colspan="1">0.79</td><td align="left" rowspan="1" colspan="1">1.61</td><td align="left" rowspan="1" colspan="1">0.516</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>Sociodemographics</italic></bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age of woman (per year increase)</bold>
</td><td align="left" rowspan="1" colspan="1">0.92</td><td align="left" rowspan="1" colspan="1">0.88</td><td align="left" rowspan="1" colspan="1">0.96</td><td align="left" rowspan="1" colspan="1">&#x0003c;.0001</td><td align="left" rowspan="1" colspan="1">0.95</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">0.99</td><td align="left" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age of man (per year increase)</bold>
</td><td align="left" rowspan="1" colspan="1">0.95</td><td align="left" rowspan="1" colspan="1">0.92</td><td align="left" rowspan="1" colspan="1">0.99</td><td align="left" rowspan="1" colspan="1">0.005</td><td colspan="4" align="left" rowspan="1">n/a</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>No. living children (per child increase)</bold>
</td><td align="left" rowspan="1" colspan="1">0.96</td><td align="left" rowspan="1" colspan="1">0.79</td><td align="left" rowspan="1" colspan="1">1.16</td><td align="left" rowspan="1" colspan="1">0.670</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Monthly household income (per 2 USD increase)</bold>
</td><td align="left" rowspan="1" colspan="1">0.99</td><td align="left" rowspan="1" colspan="1">0.99</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.069</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>Family planning and behavioral</italic></bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Woman fertility intentions</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Wants more children in the next year</td><td align="left" rowspan="1" colspan="1">1.17</td><td align="left" rowspan="1" colspan="1">0.53</td><td align="left" rowspan="1" colspan="1">2.57</td><td align="left" rowspan="1" colspan="1">0.701</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1">0.45</td><td align="left" rowspan="1" colspan="1">2.22</td><td align="left" rowspan="1" colspan="1">0.999</td></tr><tr><td align="left" rowspan="1" colspan="1">Wants more children, not in next year</td><td align="left" rowspan="1" colspan="1">1.65</td><td align="left" rowspan="1" colspan="1">1.10</td><td align="left" rowspan="1" colspan="1">2.47</td><td align="left" rowspan="1" colspan="1">0.016</td><td align="left" rowspan="1" colspan="1">1.25</td><td align="left" rowspan="1" colspan="1">0.82</td><td align="left" rowspan="1" colspan="1">1.92</td><td align="left" rowspan="1" colspan="1">0.308</td></tr><tr><td align="left" rowspan="1" colspan="1">Does not know</td><td align="left" rowspan="1" colspan="1">1.06</td><td align="left" rowspan="1" colspan="1">0.33</td><td align="left" rowspan="1" colspan="1">3.39</td><td align="left" rowspan="1" colspan="1">0.922</td><td align="left" rowspan="1" colspan="1">0.87</td><td align="left" rowspan="1" colspan="1">0.27</td><td align="left" rowspan="1" colspan="1">2.83</td><td align="left" rowspan="1" colspan="1">0.812</td></tr><tr><td align="left" rowspan="1" colspan="1">Does not want more children</td><td align="left" rowspan="1" colspan="1">ref</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ref</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Man fertility intentions</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Wants more children, not in next year</td><td align="left" rowspan="1" colspan="1">1.85</td><td align="left" rowspan="1" colspan="1">1.24</td><td align="left" rowspan="1" colspan="1">2.76</td><td align="left" rowspan="1" colspan="1">0.003</td><td align="left" rowspan="1" colspan="1">1.58</td><td align="left" rowspan="1" colspan="1">1.03</td><td align="left" rowspan="1" colspan="1">2.44</td><td align="left" rowspan="1" colspan="1">0.038</td></tr><tr><td align="left" rowspan="1" colspan="1">Does not know</td><td align="left" rowspan="1" colspan="1">1.47</td><td align="left" rowspan="1" colspan="1">0.62</td><td align="left" rowspan="1" colspan="1">3.48</td><td align="left" rowspan="1" colspan="1">0.377</td><td align="left" rowspan="1" colspan="1">1.40</td><td align="left" rowspan="1" colspan="1">0.58</td><td align="left" rowspan="1" colspan="1">3.37</td><td align="left" rowspan="1" colspan="1">0.454</td></tr><tr><td align="left" rowspan="1" colspan="1">Does not want more children</td><td align="left" rowspan="1" colspan="1">ref</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ref</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Contraception methods ever used (past or at enrollment) (ref&#x0200a;=&#x0200a;Yes)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">OCPs</td><td align="left" rowspan="1" colspan="1">1.58</td><td align="left" rowspan="1" colspan="1">1.08</td><td align="left" rowspan="1" colspan="1">2.31</td><td align="left" rowspan="1" colspan="1">0.019</td><td align="left" rowspan="1" colspan="1">1.54</td><td align="left" rowspan="1" colspan="1">1.01</td><td align="left" rowspan="1" colspan="1">2.35</td><td align="left" rowspan="1" colspan="1">0.043</td></tr><tr><td align="left" rowspan="1" colspan="1">INJ</td><td align="left" rowspan="1" colspan="1">0.93</td><td align="left" rowspan="1" colspan="1">0.61</td><td align="left" rowspan="1" colspan="1">1.40</td><td align="left" rowspan="1" colspan="1">0.719</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">IMP or IUD</td><td align="left" rowspan="1" colspan="1">0.47</td><td align="left" rowspan="1" colspan="1">0.15</td><td align="left" rowspan="1" colspan="1">1.47</td><td align="left" rowspan="1" colspan="1">0.194</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Woman has worries, concerns, or fears about (ref&#x0200a;=&#x0200a;No)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">OCPs</td><td align="left" rowspan="1" colspan="1">0.74</td><td align="left" rowspan="1" colspan="1">0.43</td><td align="left" rowspan="1" colspan="1">1.25</td><td align="left" rowspan="1" colspan="1">0.260</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">INJ</td><td align="left" rowspan="1" colspan="1">0.97</td><td align="left" rowspan="1" colspan="1">0.65</td><td align="left" rowspan="1" colspan="1">1.46</td><td align="left" rowspan="1" colspan="1">0.897</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">IMP</td><td align="left" rowspan="1" colspan="1">0.82</td><td align="left" rowspan="1" colspan="1">0.53</td><td align="left" rowspan="1" colspan="1">1.29</td><td align="left" rowspan="1" colspan="1">0.397</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">IUD</td><td align="left" rowspan="1" colspan="1">0.96</td><td align="left" rowspan="1" colspan="1">0.64</td><td align="left" rowspan="1" colspan="1">1.45</td><td align="left" rowspan="1" colspan="1">0.846</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">BTL</td><td align="left" rowspan="1" colspan="1">0.75</td><td align="left" rowspan="1" colspan="1">0.47</td><td align="left" rowspan="1" colspan="1">1.20</td><td align="left" rowspan="1" colspan="1">0.228</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Sex with partner in study in past 3 months without a condom reported by woman (time-varying), if any sex reported</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No times</td><td align="left" rowspan="1" colspan="1">ref</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;1 time</td><td align="left" rowspan="1" colspan="1">1.77</td><td align="left" rowspan="1" colspan="1">1.20</td><td align="left" rowspan="1" colspan="1">2.61</td><td align="left" rowspan="1" colspan="1">0.004</td><td align="left" rowspan="1" colspan="1">1.83</td><td align="left" rowspan="1" colspan="1">1.23</td><td align="left" rowspan="1" colspan="1">2.72</td><td align="left" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Missed OCPs (in last 3 months, time-varying)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No missed OCPs reported</td><td align="left" rowspan="1" colspan="1">ref</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Any missed OCPs reported</td><td align="left" rowspan="1" colspan="1">2.38</td><td align="left" rowspan="1" colspan="1">1.56</td><td align="left" rowspan="1" colspan="1">3.64</td><td align="left" rowspan="1" colspan="1">&#x0003c;.0001</td><td align="left" rowspan="1" colspan="1">1.86</td><td align="left" rowspan="1" colspan="1">1.18</td><td align="left" rowspan="1" colspan="1">2.91</td><td align="left" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>Health: HIV</italic></bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>HIV serostatus at enrollment</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Serodiscordant (woman is positive)</td><td align="left" rowspan="1" colspan="1">1.40</td><td align="left" rowspan="1" colspan="1">0.86</td><td align="left" rowspan="1" colspan="1">2.27</td><td align="left" rowspan="1" colspan="1">0.172</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Serodiscordant (man is positive)</td><td align="left" rowspan="1" colspan="1">1.32</td><td align="left" rowspan="1" colspan="1">0.80</td><td align="left" rowspan="1" colspan="1">2.17</td><td align="left" rowspan="1" colspan="1">0.283</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Concordant positive</td><td align="left" rowspan="1" colspan="1">ref</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Stage of HIV of woman</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">HIV negative</td><td align="left" rowspan="1" colspan="1">ref</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ref</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage I&#x02013;II</td><td align="left" rowspan="1" colspan="1">1.05</td><td align="left" rowspan="1" colspan="1">0.63</td><td align="left" rowspan="1" colspan="1">1.74</td><td align="left" rowspan="1" colspan="1">0.866</td><td align="left" rowspan="1" colspan="1">0.80</td><td align="left" rowspan="1" colspan="1">0.46</td><td align="left" rowspan="1" colspan="1">1.37</td><td align="left" rowspan="1" colspan="1">0.411</td></tr><tr><td align="left" rowspan="1" colspan="1">Stage III</td><td align="left" rowspan="1" colspan="1">0.74</td><td align="left" rowspan="1" colspan="1">0.42</td><td align="left" rowspan="1" colspan="1">1.30</td><td align="left" rowspan="1" colspan="1">0.289</td><td align="left" rowspan="1" colspan="1">0.62</td><td align="left" rowspan="1" colspan="1">0.34</td><td align="left" rowspan="1" colspan="1">1.15</td><td align="left" rowspan="1" colspan="1">0.128</td></tr><tr><td align="left" rowspan="1" colspan="1">Stage IV</td><td align="left" rowspan="1" colspan="1">0.15</td><td align="left" rowspan="1" colspan="1">0.04</td><td align="left" rowspan="1" colspan="1">0.66</td><td align="left" rowspan="1" colspan="1">0.012</td><td align="left" rowspan="1" colspan="1">0.16</td><td align="left" rowspan="1" colspan="1">0.04</td><td align="left" rowspan="1" colspan="1">0.68</td><td align="left" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Stage of HIV of man</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">HIV negative</td><td align="left" rowspan="1" colspan="1">ref</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage I&#x02013;II</td><td align="left" rowspan="1" colspan="1">0.80</td><td align="left" rowspan="1" colspan="1">0.48</td><td align="left" rowspan="1" colspan="1">1.34</td><td align="left" rowspan="1" colspan="1">0.390</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage III</td><td align="left" rowspan="1" colspan="1">0.74</td><td align="left" rowspan="1" colspan="1">0.44</td><td align="left" rowspan="1" colspan="1">1.26</td><td align="left" rowspan="1" colspan="1">0.271</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage IV</td><td align="left" rowspan="1" colspan="1">0.65</td><td align="left" rowspan="1" colspan="1">0.30</td><td align="left" rowspan="1" colspan="1">1.41</td><td align="left" rowspan="1" colspan="1">0.272</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt109"><label/><p>OCP: oral contraceptive pill; INJ: injectable contraception; IUD: intrauterine device; IMP: implant; BTL: bilateral tubal ligation; USD: United States Dollar; cHR: crude Hazard Ratio; aHR: adjusted Hazard Ratio.</p></fn><fn id="nt110"><label/><p>Additional factors evaluated and not found to be significant in the univariate analysis included: Woman understands Nyanja, man understands Nyanja, who decides when/if you should have children (reported by woman), who decides when/if you should have children (reported by man), number of lifetime sexual partners reported by woman (per partner increase), age at first intercourse reported by woman (per year increase), Method use pattern (Always continued initial method selected versus switched methods at least once during followup), and the following time varying factors: heavy menstrual bleeding, irregular bleeding, dyspareunia, lower abdominal pain, bleeding between periods, cystitis/dysuria, vaginal discharge, acute genital ulcer<bold>.</bold>
</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4"><title>Discussion</title><p>We present results from a prospective cohort of HIV discordant and concordant positive couples receiving CVCT, a video-based intervention to promote family planning, and access to the full range of contraceptive options. The overall pregnancy rate was 8.8/100CY, and ranged from 21&#x02013;26/100CY in those using OCPs or condoms only, respectively, to 0.0&#x02013;1.6/100CY among couples using injectables, LARC, or permanent methods. Remarkably, less than 10% of pregnancies were planned. Of unintended pregnancies, 87% occurred among OCP users who almost universally reported sexual exposures without a condom and missed pill doses. As these women only represented 37% of the couple-years observed, OCPs are not only the highest-risk non-barrier method, but OCP users comprised our largest risk group. For this reason, we focused our analysis on unintended pregnancies occurring among OCP users.</p><p>Women using injectables in our cohort also experienced low rates of unintended pregnancy (0.7/100CY), similar to LARC users. This is in marked contrast to other published findings of typical-use failure rates for injectables, which are higher relative to the IUD and implant. For example, Ngure et al (2012) report pregnancy rates of 6&#x02013;7/100CY for injectable using HIV serodiscordant couples from seven African countries, with no pregnancies occurring on LARC methods <xref rid="pone.0075353-Ngure1" ref-type="bibr">[40]</xref>. The high adherence to injectables we observed may be in part due to integrated family planning and HIV prevention services that included regular study visits and male partner involvement. Additionally, couples enrolled in the study were provided reimbursement for transportation thus eliminating one potential barrier for the repeat clinic visits needed for injectable adherence.</p><p>Predictors of unintended pregnancy among OCP users from our modeling analysis can target interventions to this high-risk group. Consistent with other studies in the region, we found that the younger age of the woman, the man wanting more children, and the woman reporting sex without a condom were associated with unintended pregnancy among OCP users <xref rid="pone.0075353-Wall1" ref-type="bibr">[35]</xref>, <xref rid="pone.0075353-Ngure1" ref-type="bibr">[40]</xref>&#x02013;<xref rid="pone.0075353-Kikuchi1" ref-type="bibr">[42]</xref>. In contrast with other studies, we did not find that the number of prior pregnancies was associated with unintended pregnancy.</p><p>The high prevalence of unprotected sex and its association with unintended pregnancy among OCP users underscores the challenges of combining barrier methods with effective contraception in our cohort of HIV concordant positive and discordant couples. Improved fertility based HIV prevention counseling that addresses dual method use is critical for high-risk couples. Though our limited sample size of discordant couples precluded evaluation of differences in unprotected sex across contraceptive types, we have previously published findings from Rwanda and Zambia showing that discordant couples who selected LARC methods reported significantly less unprotected sex relative to couples using condoms only <xref rid="pone.0075353-Khu1" ref-type="bibr">[43]</xref>. Additionally, although we did not find that fears or concerns about contraception were related to unintended pregnancy among OCP users, the substantial proportion of couples that expressed concern regarding contraceptive method safety highlights an important challenge for educational and social marketing programs.</p><p>Women who were new to OCP use were at higher risk of unintended pregnancy relative to women who had previous experience with the method. The ways in which women who are na&#x000ef;ve to a method differ from experienced users should be investigated further as adherence counseling may need reinforcement with new users. Additionally, reporting any missed OCPs in the prior three months was associated with unintended pregnancy. Self-reported adherence to OCPs is challenging to evaluate and often inaccurate. Women who become pregnant may be more likely to report missed pills, a potential recall bias <xref rid="pone.0075353-Pinter1" ref-type="bibr">[44]</xref>, <xref rid="pone.0075353-Stuart1" ref-type="bibr">[45]</xref>. Given that the majority of couples wished to cease or limit childbearing, promotion of LARC uptake among OCP users is indicated.</p><p>We observed that advanced HIV stage of the woman was associated with decreased unintended pregnancy incidence relative to being HIV negative. In prior studies in Rwanda, we similarly observed that the greatest reduction in incident pregnancy, after receipt of information on and access to hormonal contraception, was observed for HIV positive women <xref rid="pone.0075353-King1" ref-type="bibr">[28]</xref>, <xref rid="pone.0075353-Allen3" ref-type="bibr">[46]</xref>. However, the relationships between HIV positive serostatus, advanced HIV disease progression, fertility intentions, and pregnancy outcomes are complex. For example, HIV positive serostatus awareness and associated changes in fertility intentions do not always translate into corresponding changes contraception use, as observed among HIV positive and negative couples in northern Malawi <xref rid="pone.0075353-Dube1" ref-type="bibr">[47]</xref>, and nuanced gender-specific health concerns and fertility intentions have been observed in Malawi after an HIV diagnosis <xref rid="pone.0075353-Yeatman1" ref-type="bibr">[48]</xref>. In our study, health concerns related to advanced HIV disease may have influenced desires to avoid pregnancy, leading to more vigilant contraceptive use or reduced coital frequency, or chronic disease progression may have led to reduced coital frequency or fecundity.</p><p>It is notable that men&#x02019;s but not women&#x02019;s fertility intentions were predictive of unintended pregnancy among OCP users. This finding highlights the importance of male partner involvement and assessing fertility intentions of the couple. Considerable gender discordance between health and contraception knowledge, sexual agreements, and fertility intentions has been noted previously <xref rid="pone.0075353-Grabbe1" ref-type="bibr">[37]</xref>, <xref rid="pone.0075353-Hageman1" ref-type="bibr">[49]</xref>, <xref rid="pone.0075353-Jones1" ref-type="bibr">[50]</xref> and can be addressed by involving both members of the couple in joint family planning counseling.</p><p>In this analysis among OCP-using couples, the family planning intervention videos were not predictive of unintended pregnancy. Though exposure to the one-time video intervention influences initial method choice <xref rid="pone.0075353-Stephenson1" ref-type="bibr">[34]</xref>, it may not be enough for long-term impact, the effect overshadowed by subsequent method discontinuation or non-adherence. Repeated messaging may be required to promote method continuation and adherence.</p><p>We cannot determine from our data the potential impact of drug interactions on contraceptive failures. As indicted in the WHO Medical Eligibility Criteria, there is evidence that various drugs may reduce the efficacy of some combined hormonal contraceptives, and it is recommended to avoid these drug combinations in clinical practice. In populations where these drugs are prevalent, this would lend further support to promoting other contraceptive choices with no drug interactions, such as the IUD.</p><p>Strengths of this study include its prospective design and measurement of important time-varying health characteristics. Couples were able to select their methods of contraception thus making our findings more generalizable to a practical setting than if methods had been randomized. Additionally, in contrast to studies which use retrospective measures of unintended pregnancy, our study does not suffer from potential post-birth rationalization bias which can lead to underestimates of unintended pregnancy <xref rid="pone.0075353-Bongaarts1" ref-type="bibr">[1]</xref>. We believe assessing pregnancy intentions at the time a contraceptive method is initiated or discontinued to be a more accurate measure.</p><p>Limitations of our study include the restricted external generalizability of our findings outside of HIV prevention contexts, and a possible self-selection bias for couples with more motivation or interest in family planning who may exhibit improved overall adherence behaviors. We did not use the Bonferroni correction for multiple comparisons as little is known about predictors of unintended pregnancy and we thought this method too conservative to detect potentially weak signals &#x02013; we acknowledge therefore that our potential for type II error is higher. Finally, though we assessed several important time-varying covariates, some covariates that could potentially change during the course of the study including fertility intentions were only assessed at baseline. Though we assume that most women in our analysis, who reported continuing OCP use at each 3-month interval, were not actively trying to get pregnant, we acknowledge that fertility intentions over the three-month interval post-OCP administration may change. This is a limitation of any prospective assessment of unintended pregnancy that is restricted by assessment interval.</p></sec><sec id="s5"><title>Conclusions</title><p>Despite these limitations, our findings clearly indicate the superior efficacy of LARC methods relative to OCPs and condoms alone. We recommend that access to LARC be expanded and that these methods be promoted, particularly among HIV positive and at risk couples wishing to limit or delay fertility. Where transport is affordable and supply chains are reliable, injectables are also an effective pregnancy prevention method. Our work indicates that integration of family planning and HIV counseling and testing services, as well as male partner involvement, is an effective means to achieve this goal that should be further evaluated in non-research settings. Additionally, we recommend that LARC and injectable promotion, and methods to improve OCP adherence, be evaluated to decrease unintended pregnancy outcomes. This study indicates that these interventions could be targeted to younger HIV positive couples that are new OCP users and to those who report missed pills or unprotected sex.</p></sec></body><back><ref-list><title>References</title><ref id="pone.0075353-Bongaarts1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Bongaarts</surname><given-names>J</given-names></name>, <name><surname>Casterline</surname><given-names>J</given-names></name> (<year>2012</year>) <article-title>Fertility Transition: Is sub-Saharan Africa Different?</article-title>
<source>Population and Development Review</source>
<volume>38</volume>: <fpage>153</fpage>&#x02013;<lpage>168</lpage>.</mixed-citation></ref><ref id="pone.0075353-Demographic1"><label>2</label><mixed-citation publication-type="other">Demographic and Health Surveys (2008) STATCompiler, 2008. Available: <ext-link ext-link-type="uri" xlink:href="http://www.measuredhs.com">http://www.measuredhs.com</ext-link>. Accessed 2012 Feb 21.</mixed-citation></ref><ref id="pone.0075353-Tsui1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Tsui</surname><given-names>AO</given-names></name>, <name><surname>McDonald-Mosley</surname><given-names>R</given-names></name>, <name><surname>Burke</surname><given-names>AE</given-names></name> (<year>2010</year>) <article-title>Family planning and the burden of unintended pregnancies</article-title>. <source>Epidemiol Rev</source>
<volume>32</volume>: <fpage>152</fpage>&#x02013;<lpage>174</lpage>.<pub-id pub-id-type="pmid">20570955</pub-id></mixed-citation></ref><ref id="pone.0075353-Hobcraft1"><label>4</label><mixed-citation publication-type="other">Hobcraft J (2003) Towards a Conceptual Framework on Population, Reproductive Health, Gender and Poverty Reduction. In: UNFPA, editor. Population and Poverty: Achieving Equity, Equality and Sustainability. New York: UNFPA.</mixed-citation></ref><ref id="pone.0075353-Allen1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Allen</surname><given-names>S</given-names></name>, <name><surname>Stephenson</surname><given-names>R</given-names></name>, <name><surname>Weiss</surname><given-names>H</given-names></name>, <name><surname>Karita</surname><given-names>E</given-names></name>, <name><surname>Priddy</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Pregnancy, hormonal contraceptive use, and HIV-related death in Rwanda</article-title>. <source>J Womens Health (Larchmt)</source>
<volume>16</volume>: <fpage>1017</fpage>&#x02013;<lpage>1027</lpage>.<pub-id pub-id-type="pmid">17903079</pub-id></mixed-citation></ref><ref id="pone.0075353-Campbell1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Campbell</surname><given-names>OM</given-names></name>, <name><surname>Graham</surname><given-names>WJ</given-names></name> (<year>2006</year>) <article-title>Strategies for reducing maternal mortality: getting on with what works</article-title>. <source>Lancet</source>
<volume>368</volume>: <fpage>1284</fpage>&#x02013;<lpage>1299</lpage>.<pub-id pub-id-type="pmid">17027735</pub-id></mixed-citation></ref><ref id="pone.0075353-Adinma1"><label>7</label><mixed-citation publication-type="other">Adinma ED, Brian-D Adinma JI, Eke NO, Iwuoha C, Akiode A, <etal>et al</etal>.. (2011) Awareness and use of contraception by women seeking termination of pregnancy in south eastern Nigeria. Asian Pacific Journal of Tropical Disease: 71&#x02013;75.</mixed-citation></ref><ref id="pone.0075353-Cleland1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Cleland</surname><given-names>J</given-names></name>, <name><surname>Bernstein</surname><given-names>S</given-names></name>, <name><surname>Ezeh</surname><given-names>A</given-names></name>, <name><surname>Faundes</surname><given-names>A</given-names></name>, <name><surname>Glasier</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Family planning: the unfinished agenda</article-title>. <source>Lancet</source>
<volume>368</volume>: <fpage>1810</fpage>&#x02013;<lpage>1827</lpage>.<pub-id pub-id-type="pmid">17113431</pub-id></mixed-citation></ref><ref id="pone.0075353-Zuehlke1"><label>9</label><mixed-citation publication-type="other">Zuehlke E (2009) Reducing Unintended Pregnancy and Unsafely Performed Abortion Through Contraceptive Use. Population Reference Bureau.</mixed-citation></ref><ref id="pone.0075353-Hubacher1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Hubacher</surname><given-names>D</given-names></name>, <name><surname>Mavranezouli</surname><given-names>I</given-names></name>, <name><surname>McGinn</surname><given-names>E</given-names></name> (<year>2008</year>) <article-title>Unintended pregnancy in sub-Saharan Africa: magnitude of the problem and potential role of contraceptive implants to alleviate it</article-title>. <source>Contraception</source>
<volume>78</volume>: <fpage>73</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">18555821</pub-id></mixed-citation></ref><ref id="pone.0075353-Trussell1"><label>11</label><mixed-citation publication-type="other">Trussell J (2007) Contraceptive efficacy. In: Hatcher, RA, Trussell J, Nelson AL, Cates W, Stewart FH, <etal>et al</etal>.., editors. Contraceptive Technology, 19th revised edition. New York: Ardent Media.</mixed-citation></ref><ref id="pone.0075353-Trussell2"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Trussell</surname><given-names>J</given-names></name> (<year>1995</year>) <article-title>Contraceptive efficacy</article-title>. <source>Arch Dermatol</source>
<volume>131</volume>: <fpage>1064</fpage>&#x02013;<lpage>1068</lpage>.<pub-id pub-id-type="pmid">7661610</pub-id></mixed-citation></ref><ref id="pone.0075353-Gribble1"><label>13</label><mixed-citation publication-type="other">Gribble J, Clifton D (2010) Supply Chain: Getting Contraceptives to Users. Population Reference Bureau.</mixed-citation></ref><ref id="pone.0075353-Agha1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Agha</surname><given-names>S</given-names></name> (<year>2012</year>) <article-title>Factors associated with HIV testing and condom use in Mozambique: implications for programs</article-title>. <source>Reprod Health</source>
<volume>9</volume>: <fpage>20</fpage>.<pub-id pub-id-type="pmid">22950488</pub-id></mixed-citation></ref><ref id="pone.0075353-Nalwadda1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Nalwadda</surname><given-names>G</given-names></name>, <name><surname>Mirembe</surname><given-names>F</given-names></name>, <name><surname>Byamugisha</surname><given-names>J</given-names></name>, <name><surname>Faxelid</surname><given-names>E</given-names></name> (<year>2010</year>) <article-title>Persistent high fertility in Uganda: young people recount obstacles and enabling factors to use of contraceptives</article-title>. <source>BMC Public Health</source>
<volume>10</volume>: <fpage>530</fpage>.<pub-id pub-id-type="pmid">20813069</pub-id></mixed-citation></ref><ref id="pone.0075353-Nalwadda2"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Nalwadda</surname><given-names>G</given-names></name>, <name><surname>Mirembe</surname><given-names>F</given-names></name>, <name><surname>Tumwesigye</surname><given-names>NM</given-names></name>, <name><surname>Byamugisha</surname><given-names>J</given-names></name>, <name><surname>Faxelid</surname><given-names>E</given-names></name> (<year>2011</year>) <article-title>Constraints and prospects for contraceptive service provision to young people in Uganda: providers&#x02019; perspectives</article-title>. <source>BMC Health Serv Res</source>
<volume>11</volume>: <fpage>220</fpage>.<pub-id pub-id-type="pmid">21923927</pub-id></mixed-citation></ref><ref id="pone.0075353-Ramjee1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Ramjee</surname><given-names>G</given-names></name>, <name><surname>Kapiga</surname><given-names>S</given-names></name>, <name><surname>Weiss</surname><given-names>S</given-names></name>, <name><surname>Peterson</surname><given-names>L</given-names></name>, <name><surname>Leburg</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>The value of site preparedness studies for future implementation of phase 2/2b/3 HIV prevention trials: Experience from the hptn 055 study</article-title>. <source>Journal of Acquired Immune Deficiency Syndromes</source>
<volume>47</volume>: <fpage>93</fpage>&#x02013;<lpage>100</lpage>.<pub-id pub-id-type="pmid">17984760</pub-id></mixed-citation></ref><ref id="pone.0075353-Peterson1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Peterson</surname><given-names>L</given-names></name>, <name><surname>Taylor</surname><given-names>D</given-names></name>, <name><surname>Roddy</surname><given-names>R</given-names></name>, <name><surname>Belai</surname><given-names>G</given-names></name>, <name><surname>Phillips</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial</article-title>. <source>PLoS Clin Trials</source>
<volume>2</volume>: <fpage>e27</fpage>.<pub-id pub-id-type="pmid">17525796</pub-id></mixed-citation></ref><ref id="pone.0075353-Peterson2"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Peterson</surname><given-names>L</given-names></name>, <name><surname>Nanda</surname><given-names>K</given-names></name>, <name><surname>Opoku</surname><given-names>BK</given-names></name>, <name><surname>Ampofo</surname><given-names>WK</given-names></name>, <name><surname>Owusu-Amoako</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana</article-title>. <source>PLoS One</source>
<volume>2</volume>: <fpage>e1312</fpage>.<pub-id pub-id-type="pmid">18091987</pub-id></mixed-citation></ref><ref id="pone.0075353-Population1"><label>20</label><mixed-citation publication-type="other">Population Council (2010) &#x0201c;Jadelle.&#x0201d; Available: <ext-link ext-link-type="uri" xlink:href="http://www.popcouncil.org/what/jadelle.asp#General">http://www.popcouncil.org/what/jadelle.asp#General</ext-link>. Accessed 2013 April 11.</mixed-citation></ref><ref id="pone.0075353-United1"><label>21</label><mixed-citation publication-type="journal">
<collab>United Nations Development Programme UNPF WHO, World Bank, Special Programme of Research, Development and Research Training in Human Reproduction</collab> (<year>1997</year>) <article-title>Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C</article-title>. <source>Contraception</source>
<volume>56</volume>: <fpage>341</fpage>&#x02013;<lpage>352</lpage>.<pub-id pub-id-type="pmid">9494767</pub-id></mixed-citation></ref><ref id="pone.0075353-Hatcher1"><label>22</label><mixed-citation publication-type="other">Hatcher R, Trussell J, Nelson A, Cates W, Stewart F, <etal>et al</etal>.. (2011) Contraceptive technology. New York, NY: Ardent Media.</mixed-citation></ref><ref id="pone.0075353-Janowitz1"><label>23</label><mixed-citation publication-type="other">Janowitz B, John Bratt J, Rademacher K, Steiner M (2009) Are Contraceptive Implants Finally Affordable to Programs? International Conference on Family Planning: Research and Best Practices. Kampala, Uganda.</mixed-citation></ref><ref id="pone.0075353-Central1"><label>24</label><mixed-citation publication-type="other">Central Statistical Office (CSO), Ministry of Health (MOH), Tropical Diseases Research Centre (TDRC), et al. (2009) Zambia Demographic and Health Survey 2007. Calverton, Md: CSO and Macro International Inc.</mixed-citation></ref><ref id="pone.0075353-UNAIDSWHO1"><label>25</label><mixed-citation publication-type="other">UNAIDS/WHO (2009) Epidemiological Fact Sheet on HIV and AIDS: Zambia - 2008 Update. Geneva: UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance.</mixed-citation></ref><ref id="pone.0075353-Wilcher1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Wilcher</surname><given-names>R</given-names></name>, <name><surname>Petruney</surname><given-names>T</given-names></name>, <name><surname>Reynolds</surname><given-names>HW</given-names></name>, <name><surname>Cates</surname><given-names>W</given-names></name> (<year>2008</year>) <article-title>From effectiveness to impact: contraception as an HIV prevention intervention</article-title>. <source>Sex Transm Infect</source>
<volume>84</volume> Suppl 2<fpage>ii54</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">18799494</pub-id></mixed-citation></ref><ref id="pone.0075353-Allen2"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Allen</surname><given-names>S</given-names></name>, <name><surname>Serufilira</surname><given-names>A</given-names></name>, <name><surname>Gruber</surname><given-names>V</given-names></name>, <name><surname>Kegeles</surname><given-names>S</given-names></name>, <name><surname>Van de Perre</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>1993</year>) <article-title>Pregnancy and contraception use among urban Rwandan women after HIV testing and counseling</article-title>. <source>Am J Public Health</source>
<volume>83</volume>: <fpage>705</fpage>&#x02013;<lpage>710</lpage>.<pub-id pub-id-type="pmid">8484453</pub-id></mixed-citation></ref><ref id="pone.0075353-King1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>King</surname><given-names>R</given-names></name>, <name><surname>Estey</surname><given-names>J</given-names></name>, <name><surname>Allen</surname><given-names>S</given-names></name>, <name><surname>Kegeles</surname><given-names>S</given-names></name>, <name><surname>Wolf</surname><given-names>W</given-names></name>, <etal>et al</etal> (<year>1995</year>) <article-title>A family planning intervention to reduce vertical transmission of HIV in Rwanda</article-title>. <source>AIDS</source>
<volume>9</volume> Suppl 1<fpage>S45</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">8562000</pub-id></mixed-citation></ref><ref id="pone.0075353-Delvaux1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Delvaux</surname><given-names>T</given-names></name>, <name><surname>Nostlinger</surname><given-names>C</given-names></name> (<year>2007</year>) <article-title>Reproductive choice for women and men living with HIV: contraception, abortion and fertility</article-title>. <source>Reprod Health Matters</source>
<volume>15</volume>: <fpage>46</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">17531748</pub-id></mixed-citation></ref><ref id="pone.0075353-Imbuki1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Imbuki</surname><given-names>K</given-names></name>, <name><surname>Todd</surname><given-names>CS</given-names></name>, <name><surname>Stibich</surname><given-names>MA</given-names></name>, <name><surname>Shaffer</surname><given-names>DN</given-names></name>, <name><surname>Sinei</surname><given-names>SK</given-names></name> (<year>2010</year>) <article-title>Factors influencing contraceptive choice and discontinuation among HIV-positive women in Kericho, Kenya</article-title>. <source>Afr J Reprod Health</source>
<volume>14</volume>: <fpage>98</fpage>&#x02013;<lpage>109</lpage>.<pub-id pub-id-type="pmid">21812203</pub-id></mixed-citation></ref><ref id="pone.0075353-Nte1"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Nte</surname><given-names>AR</given-names></name>, <name><surname>Odu</surname><given-names>N</given-names></name>, <name><surname>Enyindah</surname><given-names>CE</given-names></name> (<year>2009</year>) <article-title>Male involvement in family planning: women&#x02019;s perception</article-title>. <source>Niger J Clin Pract</source>
<volume>12</volume>: <fpage>306</fpage>&#x02013;<lpage>310</lpage>.<pub-id pub-id-type="pmid">19803032</pub-id></mixed-citation></ref><ref id="pone.0075353-Utoo1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Utoo</surname><given-names>BT</given-names></name>, <name><surname>Mutihir</surname><given-names>TJ</given-names></name>, <name><surname>Utoo</surname><given-names>PM</given-names></name> (<year>2010</year>) <article-title>Knowledge, attitude and practice of family planning methods among women attending antenatal clinic in Jos, North-central Nigeria</article-title>. <source>Niger J Med</source>
<volume>19</volume>: <fpage>214</fpage>&#x02013;<lpage>218</lpage>.<pub-id pub-id-type="pmid">20642092</pub-id></mixed-citation></ref><ref id="pone.0075353-Shattuck1"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Shattuck</surname><given-names>D</given-names></name>, <name><surname>Kerner</surname><given-names>B</given-names></name>, <name><surname>Gilles</surname><given-names>K</given-names></name>, <name><surname>Hartmann</surname><given-names>M</given-names></name>, <name><surname>Ng&#x02019;ombe</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Encouraging contraceptive uptake by motivating men to communicate about family planning: the Malawi Male Motivator project</article-title>. <source>Am J Public Health</source>
<volume>101</volume>: <fpage>1089</fpage>&#x02013;<lpage>1095</lpage>.<pub-id pub-id-type="pmid">21493931</pub-id></mixed-citation></ref><ref id="pone.0075353-Stephenson1"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Stephenson</surname><given-names>R</given-names></name>, <name><surname>Vwalika</surname><given-names>B</given-names></name>, <name><surname>Greenberg</surname><given-names>L</given-names></name>, <name><surname>Ahmed</surname><given-names>Y</given-names></name>, <name><surname>Vwalika</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>A randomized controlled trial to promote long-term contraceptive use among HIV-serodiscordant and concordant positive couples in Zambia</article-title>. <source>J Womens Health (Larchmt)</source>
<volume>20</volume>: <fpage>567</fpage>&#x02013;<lpage>574</lpage>.<pub-id pub-id-type="pmid">21410332</pub-id></mixed-citation></ref><ref id="pone.0075353-Wall1"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Wall</surname><given-names>KM</given-names></name>, <name><surname>Vwalika</surname><given-names>B</given-names></name>, <name><surname>Haddad</surname><given-names>L</given-names></name>, <name><surname>Khu</surname><given-names>NH</given-names></name>, <name><surname>Vwalika</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Impact of long-term contraceptive promotion on incident pregnancy: a randomized controlled trial among HIV positive couples in Lusaka, Zambia</article-title>. <source>J Acquir Immune Defic Syndr</source>
<volume>63</volume>: <fpage>86</fpage>&#x02013;<lpage>95</lpage>.</mixed-citation></ref><ref id="pone.0075353-Stephenson2"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Stephenson</surname><given-names>R</given-names></name>, <name><surname>Barker</surname><given-names>J</given-names></name>, <name><surname>Cramer</surname><given-names>R</given-names></name>, <name><surname>Hall</surname><given-names>MA</given-names></name>, <name><surname>Karita</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>The demographic profile of sero-discordant couples enrolled in clinical research in Rwanda and Zambia</article-title>. <source>AIDS Care</source>
<volume>20</volume>: <fpage>395</fpage>&#x02013;<lpage>405</lpage>.<pub-id pub-id-type="pmid">18351489</pub-id></mixed-citation></ref><ref id="pone.0075353-Grabbe1"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Grabbe</surname><given-names>K</given-names></name>, <name><surname>Stephenson</surname><given-names>R</given-names></name>, <name><surname>Vwalika</surname><given-names>B</given-names></name>, <name><surname>Ahmed</surname><given-names>Y</given-names></name>, <name><surname>Vwalika</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Knowledge, use, and concerns about contraceptive methods among sero-discordant couples in Rwanda and Zambia</article-title>. <source>J Womens Health (Larchmt)</source>
<volume>18</volume>: <fpage>1449</fpage>&#x02013;<lpage>1456</lpage>.<pub-id pub-id-type="pmid">19708802</pub-id></mixed-citation></ref><ref id="pone.0075353-Stephenson3"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Stephenson</surname><given-names>R</given-names></name>, <name><surname>Grabbe</surname><given-names>K</given-names></name>, <name><surname>Vwalika</surname><given-names>B</given-names></name>, <name><surname>Ahmed</surname><given-names>Y</given-names></name>, <name><surname>Vwalika</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>The influence of informed consent content on study participants&#x02019; contraceptive knowledge and concerns</article-title>. <source>Stud Fam Plann</source>
<volume>41</volume>: <fpage>217</fpage>&#x02013;<lpage>224</lpage>.<pub-id pub-id-type="pmid">21331352</pub-id></mixed-citation></ref><ref id="pone.0075353-Stephenson4"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Stephenson</surname><given-names>R</given-names></name>, <name><surname>Mendenhall</surname><given-names>E</given-names></name>, <name><surname>Muzizi</surname><given-names>L</given-names></name>, <name><surname>Vwalika</surname><given-names>B</given-names></name>, <name><surname>Chomba</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>The influence of motivational messages on future planning behaviors among HIV concordant positive and discordant couples in Lusaka, Zambia</article-title>. <source>AIDS Care</source>
<volume>20</volume>: <fpage>150</fpage>&#x02013;<lpage>160</lpage>.<pub-id pub-id-type="pmid">18293123</pub-id></mixed-citation></ref><ref id="pone.0075353-Ngure1"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Ngure</surname><given-names>K</given-names></name>, <name><surname>Heffron</surname><given-names>R</given-names></name>, <name><surname>Mugo</surname><given-names>NR</given-names></name>, <name><surname>Celum</surname><given-names>C</given-names></name>, <name><surname>Cohen</surname><given-names>CR</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Contraceptive method and pregnancy incidence among women in HIV-1-serodiscordant partnerships</article-title>. <source>AIDS</source>
<volume>26</volume>: <fpage>513</fpage>&#x02013;<lpage>518</lpage>.<pub-id pub-id-type="pmid">22156966</pub-id></mixed-citation></ref><ref id="pone.0075353-Kassa1"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Kassa</surname><given-names>N</given-names></name>, <name><surname>Berhane</surname><given-names>Y</given-names></name>, <name><surname>Worku</surname><given-names>A</given-names></name> (<year>2012</year>) <article-title>Predictors of unintended pregnancy in Kersa, eastern Ethiopia, 2010</article-title>. <source>Reprod Health</source>
<volume>9</volume>: <fpage>1</fpage>.<pub-id pub-id-type="pmid">22239744</pub-id></mixed-citation></ref><ref id="pone.0075353-Kikuchi1"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Kikuchi</surname><given-names>K</given-names></name>, <name><surname>Wakasugi</surname><given-names>N</given-names></name>, <name><surname>Poudel</surname><given-names>KC</given-names></name>, <name><surname>Sakisaka</surname><given-names>K</given-names></name>, <name><surname>Jimba</surname><given-names>M</given-names></name> (<year>2011</year>) <article-title>High rate of unintended pregnancies after knowing of HIV infection among HIV positive women under antiretroviral treatment in Kigali, Rwanda</article-title>. <source>Biosci Trends</source>
<volume>5</volume>: <fpage>255</fpage>&#x02013;<lpage>263</lpage>.<pub-id pub-id-type="pmid">22281539</pub-id></mixed-citation></ref><ref id="pone.0075353-Khu1"><label>43</label><mixed-citation publication-type="journal">
<name><surname>Khu</surname><given-names>NH</given-names></name>, <name><surname>Vwalika</surname><given-names>B</given-names></name>, <name><surname>Karita</surname><given-names>E</given-names></name>, <name><surname>Kilembe</surname><given-names>W</given-names></name>, <name><surname>Bayingana</surname><given-names>RA</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Fertility goal-based counseling increases contraceptive implant and IUD use in HIV-discordant couples in Rwanda and Zambia</article-title>. <source>Contraception</source>
<volume>88(1)</volume>: <fpage>74</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">23153896</pub-id></mixed-citation></ref><ref id="pone.0075353-Pinter1"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Pinter</surname><given-names>B</given-names></name> (<year>2002</year>) <article-title>Continuation and compliance of contraceptive use</article-title>. <source>Eur J Contracept Reprod Health Care</source>
<volume>7</volume>: <fpage>178</fpage>&#x02013;<lpage>183</lpage>.<pub-id pub-id-type="pmid">12428939</pub-id></mixed-citation></ref><ref id="pone.0075353-Stuart1"><label>45</label><mixed-citation publication-type="journal">
<name><surname>Stuart</surname><given-names>GS</given-names></name>, <name><surname>Grimes</surname><given-names>DA</given-names></name> (<year>2009</year>) <article-title>Social desirability bias in family planning studies: a neglected problem</article-title>. <source>Contraception</source>
<volume>80</volume>: <fpage>108</fpage>&#x02013;<lpage>112</lpage>.<pub-id pub-id-type="pmid">19631784</pub-id></mixed-citation></ref><ref id="pone.0075353-Allen3"><label>46</label><mixed-citation publication-type="journal">
<name><surname>Allen</surname><given-names>S</given-names></name> (<year>2005</year>) <article-title>International data</article-title>. <source>J Acquir Immune Defic Syndr</source>
<volume>38</volume> Suppl 1<fpage>S7</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">15867632</pub-id></mixed-citation></ref><ref id="pone.0075353-Dube1"><label>47</label><mixed-citation publication-type="journal">
<name><surname>Dube</surname><given-names>AL</given-names></name>, <name><surname>Baschieri</surname><given-names>A</given-names></name>, <name><surname>Cleland</surname><given-names>J</given-names></name>, <name><surname>Floyd</surname><given-names>S</given-names></name>, <name><surname>Molesworth</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Fertility intentions and use of contraception among monogamous couples in northern Malawi in the context of HIV testing: a cross-sectional analysis</article-title>. <source>PLoS One</source>
<volume>7</volume>: <fpage>e51861</fpage>.<pub-id pub-id-type="pmid">23284791</pub-id></mixed-citation></ref><ref id="pone.0075353-Yeatman1"><label>48</label><mixed-citation publication-type="journal">
<name><surname>Yeatman</surname><given-names>S</given-names></name> (<year>2009</year>) <article-title>HIV infection and fertility preferences in rural Malawi</article-title>. <source>Stud Fam Plann</source>
<volume>40</volume>: <fpage>261</fpage>&#x02013;<lpage>276</lpage>.<pub-id pub-id-type="pmid">21151844</pub-id></mixed-citation></ref><ref id="pone.0075353-Hageman1"><label>49</label><mixed-citation publication-type="journal">
<name><surname>Hageman</surname><given-names>KM</given-names></name>, <name><surname>Karita</surname><given-names>E</given-names></name>, <name><surname>Kayitenkore</surname><given-names>K</given-names></name>, <name><surname>Bayingana</surname><given-names>R</given-names></name>, <name><surname>van der Straten</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>What the better half is thinking: A comparison of men&#x02019;s and women&#x02019;s responses and agreement between spouses regarding reported sexual and reproductive behaviors in Rwanda</article-title>. <source>Psychol Res Behav Manag</source>
<volume>2</volume>: <fpage>47</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">22110321</pub-id></mixed-citation></ref><ref id="pone.0075353-Jones1"><label>50</label><mixed-citation publication-type="journal">
<name><surname>Jones</surname><given-names>DL</given-names></name>, <name><surname>Villar-Loubet</surname><given-names>O</given-names></name>, <name><surname>Kankasa</surname><given-names>C</given-names></name>, <name><surname>Chitalu</surname><given-names>N</given-names></name>, <name><surname>Mumbi</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Contraception and family planning among HIV-seroconcordant and -serodiscordant couples in the US and Zambia</article-title>. <source>Open Access Journal of Contraception</source>
<volume>1</volume>: <fpage>23</fpage>&#x02013;<lpage>34</lpage>.</mixed-citation></ref></ref-list></back></article>